Arix Bioscience PLC: Transaction in own shares finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
o Revenue down 12% underlying o Cash operating income² down 13% underlying; 11% margin o Adjusted³ operating profit down 19% underlying; 9% margin o Adjusted profit before tax down 20% underlying o Adjusted EPS up 12% · Interim dividend increased +1% to 7.6p · Statutory · Active portfolio management strategy delivering value creation: o Increased investment in Cazoo in October 2020; proposed transaction values stake at c.US$1.35bn
5 vs £117m total investment o Disposal of EdTech (Hobsons) for c.US$410m in March 2021 o Acquisition of New Scientist for £67m in March 2021 · Strong financial position maintained: pro forma net cash £293m
6 and £362m of committed undrawn bank facilities; statutory net cash £199m
Arix Bioscience PLC: Transaction in own shares
DJ Transaction in own shares
Arix Bioscience PLC (ARIX)
Transaction in own shares
26-May-2021 / 16:52 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=
Arix Bioscience plc
Transaction in own shares
LONDON, 26 May 2021: Arix Bioscience plc ( Arix or the Company ) (LSE:ARIX), a global venture capital company focused
on investing in and building breakthrough biotech companies, today announces that it purchased the following number of
its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a